{"a":[{"_":"With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’","$":{"href":"/biotech/pioneering-adhd-data-alkermes-eyes-orexin-agonist-potential-company-changer","hreflang":"en"}}]}

Data ReadoutpositiveOrzeyfulPositive

AI Analysis

Summary

Alkermes has released pioneering ADHD data for an orexin agonist, following Takeda's recent FDA approval of Orzeyful for narcolepsy, potentially expanding the drug class beyond sleep disorders.

Outcome Details

Pioneering ADHD data with orexin agonist

Importance:6/10

Sentiment:

0.70

ADHDorexin agonistclinical datadrug developmentnarcolepsy

Related Companies

$TAK $TRAX

Read the original article

Published by FierceBiotech on September 18, 2026 12:36 PM

Read Original